Department of Experimental and Clinical Medicine, University Magna-Graecia of Catanzaro, Via Europa, 88100 Catanzaro, Italy.
Eur J Endocrinol. 2010 Jul;163(1):75-80. doi: 10.1530/EJE-10-0113. Epub 2010 Mar 31.
Low IGF1 levels have been associated with an increased cardiovascular risk. It is unknown however whether IGF1 mediates the atherosclerotic process by modulating high-density lipoprotein cholesterol (HDL-C) independently from confounders. To address this issue, we evaluated the association between IGF1 levels and HDL-C in nondiabetic subjects.
A cross-sectional analysis was used in the context of the CAtanzaro MEtabolic RIsk factors Study. One thousand and four participants (aged 20-69 years), for whom HDL-C and IGF1 measurements were available, were eligible for the study.
After adjusting for gender and age, IGF1 levels were positively correlated with HDL-C, and negatively correlated with body mass index (BMI), waist circumference, blood pressure (BP), triglyceride, fasting insulin, and homeostasis model assessment (HOMA). In a logistic regression model adjusted for age and gender, IGF1 in the lowest tertile (<125 ng/ml) was associated with an increased risk of having low HDL-C (odds ratio (OR) 2.14, 95% confidence interval (CI) 1.4-3.0; P=4x10(-5)) compared with the highest tertile (>186 ng/ml). When BMI, waist circumference, total cholesterol, triglyceride, and HOMA index were added to the model, IGF1 remained significantly associated with increased risk of low HDL-C (OR 1.52, 95% CI 1.01-2.31; P=0.04). A stepwise multivariate regression analysis in a model including age, gender, BMI, total cholesterol, triglycerides, IGF1, HOMA, and BP showed that the variables significantly associated with HDL-C were gender (P<0.0001), triglycerides (P<0.0001), total cholesterol (P<0.0001), BMI (P<0.0001), IGF1 levels (P<0.0001), and HOMA (P=0.001), accounting for 32.6% of its variation.
These data provide evidence that IGF1 may be an independent modulator for HDL-C in nondiabetic individuals.
低 IGF1 水平与心血管风险增加有关。然而,IGF1 是否通过调节高密度脂蛋白胆固醇(HDL-C)来介导动脉粥样硬化过程,而与混杂因素无关,目前尚不清楚。为了解决这个问题,我们评估了非糖尿病患者中 IGF1 水平与 HDL-C 之间的关系。
在卡坦扎罗代谢危险因素研究的背景下进行了横断面分析。共有 1040 名(年龄 20-69 岁)可测量 HDL-C 和 IGF1 的参与者符合研究条件。
在调整性别和年龄后,IGF1 水平与 HDL-C 呈正相关,与体重指数(BMI)、腰围、血压(BP)、甘油三酯、空腹胰岛素和稳态模型评估(HOMA)呈负相关。在调整年龄和性别后的逻辑回归模型中,IGF1 处于最低三分位(<125ng/ml)的个体与 HDL-C 降低的风险增加相关(比值比(OR)为 2.14,95%置信区间(CI)为 1.4-3.0;P=4x10(-5))与最高三分位(>186ng/ml)相比。当将 BMI、腰围、总胆固醇、甘油三酯和 HOMA 指数添加到模型中时,IGF1 与 HDL-C 降低的风险增加仍然显著相关(OR 为 1.52,95%CI 为 1.01-2.31;P=0.04)。在包括年龄、性别、BMI、总胆固醇、甘油三酯、IGF1、HOMA 和 BP 的模型中进行逐步多元回归分析表明,与 HDL-C 显著相关的变量是性别(P<0.0001)、甘油三酯(P<0.0001)、总胆固醇(P<0.0001)、BMI(P<0.0001)、IGF1 水平(P<0.0001)和 HOMA(P=0.001),占其变异性的 32.6%。
这些数据提供了证据表明,IGF1 可能是非糖尿病个体中 HDL-C 的独立调节剂。